By Tyler Durden
A few days ago, researchers in South Africa shared data from a preliminary study showing that the Pfizer vaccine is less effective at blocking the omicron variant than earlier variants like beta and delta. Now, the team is telling us exactly how much less effective the vaccine is.
According to the same data gleaned from the blood plasma taken from 12 patients who tested positive for omicron, the team found that a two-shot course of Pfizer’s vaccine has just 22.5% efficacy against symptomatic infection with the omicron variant, though it can thwart severe disease, according to laboratory experiments in South Africa, according to Bloomberg.
The data comes courtesy of a team of researchers at the Africa Health Research Institute in Durban.
